Ontario Invests $5M in Early-Stage Biotech Companies

The $5 million provincial investment is part of a $19.3 million round that also includes private-sector co-investment for Ontario health technology companies. 

The Ontario government is investing $5 million in 10 life sciences companies through the fourth round of its Life Sciences Innovation Fund.

The provincial funding is part of a $19.3 million round that includes $14.3 million in private-sector co-investment, according to the Ontario Centre of Innovation. The money will support companies working on medical technologies, drug discovery platforms, diagnostics and digital health tools.

Each company will receive up to $500,000 to move its technology closer to commercialization.

The 10 recipients are Esphera SynBio, Kare Chemical Technologies, Myomar Molecular, MyStoria, mDETECT, NodeAI, ScriptRunner Innovations, Stoked Bio, Synakis and Synmedix. The companies span AI diagnostics, liquid biopsy testing, antibiotic development, drug discovery, reproductive healthcare, pharmacy delivery and non-invasive disease monitoring.

Among the funded companies, mDETECT is developing DNA-methylation liquid biopsy technology for metastatic cancers. NodeAI is building an AI platform to support lymph node assessment and biopsy guidance, while Synmedix is developing antibiotics for serious drug-resistant infections.

Xtalks Insights

Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.

First Name *

Email *

By clicking this checkbox, I agree to receive Xtalks communications and understand that I may unsubscribe at any time. Please review the Xtalks privacy policy here.

Protected by reCAPTCHA.

Continue

What topics would you like to hear more about?

Select all that apply.

Science and Discovery Clinical Development Regulatory Safety and Quality Manufacturing and Supply Chain Commercial and Market Access Data AI and Digital Therapeutic Areas

Progress

1 2 3

Next Step

Want to get even more specific?

Help us narrow down the sub-topics that you're most interested in.

Progress

1 2 3

Save Preferences

Thank you!

For webinars, videos, podcasts and more from Xtalks, join our community today.

BECOME A FREE MEMBER

Progress

1 2 3

The Ontario Centre of Innovation manages the fund. Across its first four funding rounds, the Life Sciences Innovation Fund has helped create and retain 1,399 jobs.

Ontario renewed the fund in its 2025 budget with an additional $15 million over three years. The budget also included $40 million for venture capital funds focused on life sciences companies and biomanufacturers.

Ontario Draws New AI, Biotech and Radiopharma Investments

Ontario is gaining life sciences investments across AI, microbiome-based therapies, biopharma operations and radiopharmaceutical manufacturing.

In 2026, French drugmaker Sanofi announced a $294 million expansion of its global AI Centre of Excellence in Toronto in May. The project could add 50 AI and machine learning jobs and support AI tools used across Sanofi’s global research, manufacturing and business operations.

Toronto-based biotech company Ostia Sciences will invest $12 million over three years to expand R&D for microbiome-based therapeutics in Ontario. The project includes $5 million in R&D investment, could create 28 jobs and will support the company’s platform for identifying bacteria with drug-like properties and producing bacteriocins, a type of antimicrobial molecule.

UCB Canada, a biopharma company, announced a multi-million-dollar expansion of its Oakville operations. The project will add 28 jobs across medical, commercial, market access and other specialized roles.

Last December, AtomVie Global Radiopharma planned to invest more than $138 million in a new manufacturing facility in Hamilton. The facility would increase AtomVie’s radiopharmaceutical manufacturing capacity by at least tenfold and support clinical trial and commercial programs for targeted cancer therapies.

At the federal level, Canada has also recently announced $66 million for 44 AI projects, including tools for drug discovery, and $29.2 million for Talent Innovation Canada, a new organization that will place graduate, PhD and postdoctoral researchers in companies working in areas including biomanufacturing and life sciences.